{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:04:49Z","timestamp":1648667089189},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[1995,10,1]],"date-time":"1995-10-01T00:00:00Z","timestamp":812505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[1995,10]]},"DOI":"10.1016\/0959-8049(95)00384-u","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T23:06:17Z","timestamp":1027638377000},"page":"1773-1777","source":"Crossref","is-referenced-by-count":2,"title":["Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"H.","family":"Gurney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Stuart-Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kefford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/0959-8049(95)00384-U_BIB1","first-page":"56","article-title":"Salvage chemotherapy for metastatic breast cancer","volume":"24","author":"Hortobagyi","year":"1987"},{"key":"10.1016\/0959-8049(95)00384-U_BIB2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF01806525","article-title":"Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer","volume":"13","author":"Buckner","year":"1989","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/0959-8049(95)00384-U_BIB3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/oxfordjournals.annonc.a058411","article-title":"Escalating drug delivery in cancer chemotherapy: a review of concepts and practice\u2014part 2","volume":"4","author":"Gurney","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB4","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1992.10.11.1743","article-title":"High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report","volume":"10","author":"Williams","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199111073251904","article-title":"Interrupted versus continuous chemotherapy in patients with metastatic breast cancer","volume":"325","author":"Muss","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/0959-8049(95)00384-U_BIB6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00000421-198902000-00014","article-title":"A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer","volume":"12","author":"Hortobagyi","year":"1989","journal-title":"AmJ Clin Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB7","first-page":"775","article-title":"Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion","volume":"65","author":"Yap","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/0959-8049(95)00384-U_BIB8","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/1097-0142(19900601)65:11<2421::AID-CNCR2820651103>3.0.CO;2-L","article-title":"Phase II study of doxorubicin and ifosfamide\/mesna in patients with advanced breast cancer","volume":"65","author":"Millward","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/0959-8049(95)00384-U_BIB9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0140-6736(90)90053-8","article-title":"Ifosfamide by continuous infusion to prevent encephalopathy","volume":"335","author":"Cerny","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/0959-8049(95)00384-U_BIB10","first-page":"2209","article-title":"In vivo pertubation of human marrow cell cycle progression by ifosfamide","volume":"38","author":"Rentschler","year":"1978","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00384-U_BIB11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF02897261","article-title":"The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumps","volume":"26","author":"Radford","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB12","first-page":"220","article-title":"Stability of anthracycline antitumour agents in infusional fluids","volume":"39","author":"Beijnen","year":"1985","journal-title":"J Parenler Sci Technol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0378-5173(89)90121-X","article-title":"Degradation kinetics of vincristine sulphate and vindesine sulphate in aqueous solution","volume":"50","author":"Vendrig","year":"1989","journal-title":"Int J Pharm"},{"key":"10.1016\/0959-8049(95)00384-U_BIB14","first-page":"3022","article-title":"Stability of intravenous mixtures of doxorubicin and vincristine","volume":"43","author":"Beijnen","year":"1986","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/0959-8049(95)00384-U_BIB15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00001813-199212000-00006","article-title":"Interaction of epirubicin with other cytotoxics and anti-emetic drugs","volume":"3","author":"Zhang","year":"1992","journal-title":"Anticancer Drugs"},{"key":"10.1016\/0959-8049(95)00384-U_BIB16","first-page":"58","article-title":"Phase I study of an outpatient continuous infusion of ifosfamide, mesna, epirubicin, and vincristine","volume":"18","author":"Gurney","year":"1991"},{"key":"10.1016\/0959-8049(95)00384-U_BIB17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0360-3016(88)90053-3","article-title":"The efficacy of combined chemotherapy and radiotherapy in advanced non-metastatic breast cancer","volume":"14","author":"Boyages","year":"1987","journal-title":"Int J Radiat Oncol BiolPhys"},{"key":"10.1016\/0959-8049(95)00384-U_BIB18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/oxfordjournals.annonc.a058348","article-title":"Escalating drug delivery in cancer chemotherapy: a review of concepts and practice\u2014part 1","volume":"4","author":"Gurney","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1200\/JCO.1988.6.9.1377","article-title":"A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer","volume":"6","author":"Tannock","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.1990.8.7.1207","article-title":"Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support","volume":"8","author":"Dunphy","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB21","first-page":"63","article-title":"Lack of clinical cross resistance of taxol with anthracycline in the treatment of metastatic breast cancer","volume":"12","author":"Seidman","year":"1993"},{"key":"10.1016\/0959-8049(95)00384-U_BIB22","first-page":"470","article-title":"Phase II study of docetaxol (taxotere) in anthracycline refractory metastatic breast cancer","volume":"13","author":"Valero","year":"1994"},{"key":"10.1016\/0959-8049(95)00384-U_BIB23","first-page":"57","article-title":"Predicting the response of advanced breast cancer to successive chemotherapy regimens","volume":"12","author":"Gregory","year":"1993"},{"key":"10.1016\/0959-8049(95)00384-U_BIB24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1200\/JCO.1994.12.8.1639","article-title":"Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer","volume":"12","author":"Porkka","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB25","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1200\/JCO.1991.9.10.1731","article-title":"Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well tolerated regimen for metastatic breast cancer","volume":"9","author":"Hainsworth","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/0959-8049(95)00384-U_BIB26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/1097-0142(19870115)59:2<239::AID-CNCR2820590211>3.0.CO;2-C","article-title":"Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens: a Southwest Oncology Group Study","volume":"59","author":"Ahmann","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/0959-8049(95)00384-U_BIB27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9610(05)80686-5","article-title":"Thrombolytic therapy for catheter-related thrombosis","volume":"166","author":"Seigel","year":"1993","journal-title":"Am J Surg"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:095980499500384U?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:095980499500384U?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T12:20:12Z","timestamp":1555590012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/095980499500384U"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,10]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1995,10]]}},"alternative-id":["095980499500384U"],"URL":"https:\/\/doi.org\/10.1016\/0959-8049(95)00384-u","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[1995,10]]}}}